These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
832 related articles for article (PubMed ID: 27592396)
1. New piperidine-hydrazone derivatives: Synthesis, biological evaluations and molecular docking studies as AChE and BChE inhibitors. Karaman N; Sıcak Y; Taşkın-Tok T; Öztürk M; Karaküçük-İyidoğan A; Dikmen M; Koçyiğit-Kaymakçıoğlu B; Oruç-Emre EE Eur J Med Chem; 2016 Nov; 124():270-283. PubMed ID: 27592396 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, molecular modeling, in vitro evaluation of novel piperidine-containing hydrazone derivatives as cholinesterase inhibitors. Tok F; Baltaş N; Abas Bİ; Tatar Yılmaz G; Kaya S; Koçyiğit-Kaymakçıoğlu B; Çevik Ö Drug Dev Res; 2024 Aug; 85(5):e22240. PubMed ID: 39105636 [TBL] [Abstract][Full Text] [Related]
3. A Series of New Hydrazone Derivatives: Synthesis, Molecular Docking and Anticholinesterase Activity Studies. Bozbey İ; Özdemir Z; Uslu H; Özçelik AB; Şenol FS; Orhan İE; Uysal M Mini Rev Med Chem; 2020; 20(11):1042-1060. PubMed ID: 31660824 [TBL] [Abstract][Full Text] [Related]
4. Novel fluorine-containing chiral hydrazide-hydrazones: Design, synthesis, structural elucidation, antioxidant and anticholinesterase activity, and in silico studies. Sıcak Y; Oruç-Emre EE; Öztürk M; Taşkın-Tok T; Karaküçük-Iyidoğan A Chirality; 2019 Aug; 31(8):603-615. PubMed ID: 31222828 [TBL] [Abstract][Full Text] [Related]
5. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics. Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794 [TBL] [Abstract][Full Text] [Related]
6. Synthesis, Biological Evaluation and Molecular Docking Study of Hydrazone-Containing Pyridinium Salts as Cholinesterase Inhibitors. Parlar S; Bayraktar G; Tarikogullari AH; Alptüzün V; Erciyas E Chem Pharm Bull (Tokyo); 2016; 64(9):1281-7. PubMed ID: 27581632 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and evaluation of novel cinnamic acid-tryptamine hybrid for inhibition of acetylcholinesterase and butyrylcholinesterase. Ghafary S; Ghobadian R; Mahdavi M; Nadri H; Moradi A; Akbarzadeh T; Najafi Z; Sharifzadeh M; Edraki N; Moghadam FH; Amini M Daru; 2020 Dec; 28(2):463-477. PubMed ID: 32372339 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer's Disease. Hussein W; Sağlık BN; Levent S; Korkut B; Ilgın S; Özkay Y; Kaplancıklı ZA Molecules; 2018 Aug; 23(8):. PubMed ID: 30110946 [TBL] [Abstract][Full Text] [Related]
9. Synthesis of new donepezil analogues and investigation of their effects on cholinesterase enzymes. Sağlık BN; Ilgın S; Özkay Y Eur J Med Chem; 2016 Nov; 124():1026-1040. PubMed ID: 27783974 [TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Evaluation of Acetylcholinesterase and Butyrylcholinesterase Dual-Target Inhibitors against Alzheimer's Diseases. Guo Y; Yang H; Huang Z; Tian S; Li Q; Du C; Chen T; Liu Y; Sun H; Liu Z Molecules; 2020 Jan; 25(3):. PubMed ID: 31979317 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors. Gao CZ; Dong W; Cui ZW; Yuan Q; Hu XM; Wu QM; Han X; Xu Y; Min ZL J Enzyme Inhib Med Chem; 2019 Dec; 34(1):150-162. PubMed ID: 30427217 [TBL] [Abstract][Full Text] [Related]
12. Bioactive sulfonyl hydrazones with alkyl derivative: Characterization, ADME properties, molecular docking studies and investigation of inhibition on choline esterase enzymes for the diagnosis of Alzheimer's disease. Bilen E; Özdemir Özmen Ü; Çete S; Alyar S; Yaşar A Chem Biol Interact; 2022 Jun; 360():109956. PubMed ID: 35452634 [TBL] [Abstract][Full Text] [Related]
13. Pyridine sulfonamide as a small key organic molecule for the potential treatment of type-II diabetes mellitus and Alzheimer's disease: In vitro studies against yeast α-glucosidase, acetylcholinesterase and butyrylcholinesterase. Riaz S; Khan IU; Bajda M; Ashraf M; Qurat-Ul-Ain ; Shaukat A; Rehman TU; Mutahir S; Hussain S; Mustafa G; Yar M Bioorg Chem; 2015 Dec; 63():64-71. PubMed ID: 26451651 [TBL] [Abstract][Full Text] [Related]
14. Synthesis, pharmacological assessment, molecular modeling and in silico studies of fused tricyclic coumarin derivatives as a new family of multifunctional anti-Alzheimer agents. Shaik JB; Palaka BK; Penumala M; Kotapati KV; Devineni SR; Eadlapalli S; Darla MM; Ampasala DR; Vadde R; Amooru GD Eur J Med Chem; 2016 Jan; 107():219-32. PubMed ID: 26588065 [TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of some new carboxamide and propanamide derivatives bearing phenylpyridazine as a core ring and the investigation of their inhibitory potential on in-vitro acetylcholinesterase and butyrylcholinesterase. Kilic B; Gulcan HO; Aksakal F; Ercetin T; Oruklu N; Umit Bagriacik E; Dogruer DS Bioorg Chem; 2018 Sep; 79():235-249. PubMed ID: 29775949 [TBL] [Abstract][Full Text] [Related]